240 related articles for article (PubMed ID: 12467215)
1. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Shabbits JA; Mayer LD
Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
[TBL] [Abstract][Full Text] [Related]
2. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Sietsma H; Veldman RJ; Kolk D; Ausema B; Nijhof W; Kamps W; Vellenga E; Kok JW
Clin Cancer Res; 2000 Mar; 6(3):942-8. PubMed ID: 10741719
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Norris-Cervetto E; Callaghan R; Platt FM; Dwek RA; Butters TD
J Biol Chem; 2004 Sep; 279(39):40412-8. PubMed ID: 15263008
[TBL] [Abstract][Full Text] [Related]
4. Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells.
Plo I; Lehne G; Beckstrøm KJ; Maestre N; Bettaïeb A; Laurent G; Lautier D
Mol Pharmacol; 2002 Aug; 62(2):304-12. PubMed ID: 12130682
[TBL] [Abstract][Full Text] [Related]
5. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
6. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
7. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
9. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.
Olshefski RS; Ladisch S
Int J Cancer; 2001 Jul; 93(1):131-8. PubMed ID: 11391632
[TBL] [Abstract][Full Text] [Related]
10. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein.
Smith CD; Myers CB; Zilfou JT; Smith SN; Lawrence DS
Oncol Res; 2000; 12(5):219-29. PubMed ID: 11417747
[TBL] [Abstract][Full Text] [Related]
11. Cytoprotective effect of glucosylceramide synthase inhibition against daunorubicin-induced apoptosis in human leukemic cell lines.
Grazide S; Terrisse AD; Lerouge S; Laurent G; Jaffrézou JP
J Biol Chem; 2004 Apr; 279(18):18256-61. PubMed ID: 14766899
[TBL] [Abstract][Full Text] [Related]
12. Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells.
di Bartolomeo S; Spinedi A
Biochem Biophys Res Commun; 2001 Oct; 288(1):269-74. PubMed ID: 11594784
[TBL] [Abstract][Full Text] [Related]
13. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.
Gouazé-Andersson V; Yu JY; Kreitenberg AJ; Bielawska A; Giuliano AE; Cabot MC
Biochim Biophys Acta; 2007 Dec; 1771(12):1407-17. PubMed ID: 18035065
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
Gouazé V; Yu JY; Bleicher RJ; Han TY; Liu YY; Wang H; Gottesman MM; Bitterman A; Giuliano AE; Cabot MC
Mol Cancer Ther; 2004 May; 3(5):633-9. PubMed ID: 15141021
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
17. The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244.
Wang T; Wei J; Wang N; Ma JL; Hui PP
Biochem Biophys Res Commun; 2015 Jan; 456(3):821-6. PubMed ID: 25498501
[TBL] [Abstract][Full Text] [Related]
18. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.
Chapman JV; Gouazé-Andersson V; Karimi R; Messner MC; Cabot MC
Exp Cell Res; 2011 Jul; 317(12):1736-45. PubMed ID: 21396934
[TBL] [Abstract][Full Text] [Related]
20. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
